Широко нейтрализующие антитела для лечения ВИЧ-инфекции
https://doi.org/10.22328/2077-9828-2021-13-3-81-95
Аннотация
Антитела, обладающие нейтрализующей активностью в отношении широкого спектра субтипов вируса иммунодефицита человека 1 (обозначаемые термином broadly neutralizing antibodies — bnAbs), представляют огромный интерес в качестве терапевтического агента для лечения ВИЧ-инфекции, поскольку при пассивной иммунизации они способны обеспечить защиту от большинства штаммов ВИЧ-1. В представленном обзоре обсуждаются механизмы формирования таких антител, их классификация по связыванию с консервативными областями оболочечного белка Env, а также присущие им особенности. Приведены данные по характеристикам наиболее перспективных для терапии bnAbs, а также их комбинаций.
В последнем разделе рассмотрены уже имеющиеся на сегодняшний день результаты клинических испытаний широко нейтрализующих антител 3BNC117, VRC01 и 10-1074. При их анализе можно сделать важный вывод: введение только одного антитела сопровождается появлением резистентных вирусных вариантов. Результаты исследования единственной пока комбинации антител 3BNC117 и 10-1074 показывают, что такая терапия более эффективна и позволяет достичь длительной супрессии вируса у части пациентов. О перспективности комбинированной иммунотерапии ВИЧ свидетельствует инициация большого числа клинических испытаний комбинаций из двух или более широко нейтрализующих антител.
Об авторах
Д. В. Глазкова
Центр стратегического планирования и управления медико-биологическими рисками здоровью
Россия
Россия
Глазкова Дина Викторовна — кандидат биологических наук, старший научный сотрудник
119121, Москва, Погодинская ул., д. 10, стр. 1
SPIN 4468–9003
Е. В. Богословская
Центр стратегического планирования и управления медико-биологическими рисками здоровью
Россия
Россия
Богословская Елена Владимировна — доктор медицинских наук, заведующий лабораторией разработки методов генной терапии
119121, Москва, Погодинская ул., д. 10, стр. 1
SPIN-код 4062–3678
Г. А. Шипулин
Центр стратегического планирования и управления медико-биологическими рисками здоровью
Россия
Россия
Шипулин Герман Александрович — кандидат медицинских наук, заместитель директора по научно-производственной деятельности
119121, Москва, Погодинская ул., д. 10, стр. 1
SPIN-код 1908–9098
С. М. Юдин
Центр стратегического планирования и управления медико-биологическими рисками здоровью
Россия
Россия
Юдин Сергей Михайлович — доктор медицинских наук, профессор, генеральный директор
119121, Москва, Погодинская ул., д. 10, стр. 1
SPIN-код 9706–5936
Список литературы
1. Wang Q. and Zhang L. Broadly neutralizing antibodies and vaccine design against HIV-1 infection // Front Med. 2020. Vol. 14, No. 1. Р. 30– 42. doi: 10.1007/s11684-019-0721-9.
2. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes // Nature. 2006. Vol. 441, No. 7095. Р. 847–852. doi: 10.1038/nature04817.
3. Wyatt R., Sodroski J. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens // Science. 1998. Vol. 280, No. 5371. Р. 1884– 1888. doi: 10.1126/science.280.5371.1884.
4. Stewart-Jones G.B.E., Soto C., Lemmin T., Chuang G.Y. et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G // Cell. 2016. Vol. 165, No. 4. Р. 813–826. doi: 10.1016/j.cell.2016.04.010.
5. Walker L.M., Phogat S.K., Chan-Hui Po-Y., Wagner D. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV- 1 vaccine target // Science. 2009. Vol. 326, No. 5950. Р. 285–289. doi: 10.1126/science.1178746.
6. Alam S.M., McAdams M., Boren D., Rak M. et al. The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes. // J. Immunol. 2007. Vol. 178, No. 7. Р. 4424–4235. doi: 10.4049/jimmunol.178.7.4424.
7. Liao H.-X., Chen Xi, Munshaw S., Zhang R. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated // J. Exp. Med. 2011. Vol. 208, No. 11. Р. 2237–2249. doi: 10.1084/jem.20110363.
8. Haynes B.F., Fleming J., Clair E.W.St. et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies // Science. 2005. Vol. 308, No. 5730. Р. 1906–1908. doi: 10.1126/science.1111781.
9. Matyas G.R., Beck Z., Karasavvas N., Alving C.R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV- 1 // Biochim. Biophys. Acta. 2009. Vol. 1788, No. 3. Р. 660–665. doi: 10.1016/j.bbamem.2008.11.015.
10. Barbas C.F. III, Björling E., Chiodi F., Dunlop N., Cababa D. et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro // Proc. Natl. Acad. Sci. USA. 1992. Vol. 89(19. Р. 9339–9343. doi: 10.1073/pnas.89.19.9339.
11. Burton D., Pyati J., Koduri R., Sharp S.J. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody // Science. 1994. Vol. 266, No. 5187. Р. 1024–1027. doi: 10.1126/science.7973652.
12. Gorny M.K., Conley A.J., Karwowska S., Buchbinder A., Xu J.Y., Emini E.A., Koenig S., Zolla-Pazner S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody // J. Virol. 1992. Vol. 66, No. 12. P. 7538–7542. doi: 10.1128/JVI.66.12.7538-7542.1992.
13. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 // J. Virol. 1993. Vol. 67, No. 11. Р. 6642–6647. doi: 10.1128/JVI.67.11.6642-6647.1993.
14. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1 // AIDS Res. Hum. Retroviruses. 2001. Vol. 17, No. 18. Р. 1757–1765. doi: 10.1089/08892220152741450.
15. Zwick M.B., Labrijn A.F., Wang M., Spenlehaueret C. et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 // J. Virol. 2001. Vol. 75, No. 22. Р. 10892–10905. doi: 10.1128/JVI.75.22.10892-10905.2001.
16. Wei X., Decker J.M., Wang S., Hui H. et al. Antibody neutralization and escape by HIV-1. // Nature. 2003. Vol. 422, No. 6929. Р. 307–312. doi: 10.1038/nature01470.
17. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100, No. 7. Р. 4144–4149. doi: 10.1073/pnas.0630530100.
18. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: understanding nature’s pathways. // Immunol. Rev. 2013. Vol. 254, No. 1. Р. 225– 244. doi: 10.1111/imr.12075.
19. Rusert P., Kouyos R.D., Kadelka C., Ebner H. et al. Determinants of HIV-1 broadly neutralizing antibody induction. // Nat. Med. 2016. Vol. 22, No. 11. Р. 1260–1267. doi: 10.1038/nm.4187.
20. Subbaraman H., Schanz M., Trkola A. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? // Retrovirology. 2018. Vol. 15, No. 1. Р. 52. doi: 10.1186/s12977-018-0433-2.
21. Dugast A.-S., Arnold K., Lofano G., Moore S. et al. Virus-driven Inflammation Is Associated with the Development of bNAbs in Spontaneous Controllers of HIV // Clin. Infect. Dis. 2017. Vol. 64, No. 8. Р. 1098–1104. doi: 10.1093/cid/cix057.
22. Aasa-Chapman M.M., Hayman A., Newton P., Cornforth D. et al. Development of the antibody response in acute HIV-1 infection // AIDS. 2004. Vol. 18, No. 3. Р. 371–381. doi: 10.1097/00002030–200402200–00002.
23. Mikell I., Sather D.N., Kalams S.A., Altfeld M., Alter G., Stamatatos L. et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 // PLoS Pathog. 2011. Vol. 7, No. 1. Р. e1001251. doi: 10.1371/journal.ppat.1001251.
24. Landais E., Moore P.L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. // Retrovirology. 2018. Vol. 15, No. 1. Р. 61. doi: 10.1186/s12977-018-0443-0.
25. Doria-Rose N.A., Schramm C.A., Gorman J., Moore P.L. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies // Nature. 2014. Vol. 509, No. 7498. Р. 55–62. doi: 10.1038/nature13036.
26. Klein F., Diskin R., Scheid J.F., Gaebler C. -et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization // Cell. 2013. Vol. 153, No. 1. Р. 126–138. doi: 10.1016/j.cell.2013.03.018.
27. Kepler T.B., Liao H.-X., Alam S.M., Bhaskarabhatla R. et al. Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies // Cell Host Microbe. 2014. Vol. 16, No. 3. Р. 304–313. doi: 10.1016/j.chom.2014.08.006.
28. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant Autoantibody Production by Early Human B Cell Precursors // Science. 2003. Vol. 301, No. 5638. Р. 1374–1377. doi: 10.1126/science.1086907.
29. Mouquet H., Scheid J.F., Zoller M.J., Krogsgaard M. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation // Nature. 2010. Vol. 467, No. 7315. Р. 591–595. doi: 10.1038/nature09385.
30. Diskin R., Scheid J.F., Marcovecchio P.M. et al. Increasing the Potency and Breadth of an HIV Antibody by using Structure-Based Rational Design // Science. 2011. Vol. 334, No. 6060. Р. 1289–1293. doi: 10.1126/science.1213782.
31. Yang G., Holl TM., Liu Y., Li Y., Lu X. et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies // J. Exp. Med. 2013. Vol. 210, No. 2. Р. 241–256. doi: 10.1084/jem.20121977.
32. Scheid J.F., Mouquet H., Ueberheide B., Diskin R. et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding // Science. 2011. Vol. 333, No. 6049. Р. 1633–1637. doi: 10.1126/science.1207227.
33. Zhou P., Wang H., Fang M., Li Y. et al. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies // PLOS Pathog. 2019. Vol. 15, No. 6. P. e1007819. doi: 10.1371/journal.ppat.1007819.
34. Asokan M., Rudicell R.S., Louder M., McKee K. et al. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization // J. Virol. 2015. Vol. 89, No. 24. Р. 12501–12512. doi: 10.1128/JVI.02097-15.
35. Wagh K., Seaman M.S., Zingg M., Fitzsimons T. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections // PLoS Pathog. 2018. Vol. 14, No. 3. e1006860. doi: 10.1371/journal.ppat.1006860.
36. Xu L., Pegu A., Rao E., Doria-Rose N. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques // Science. 2017. Vol. 358, No. 6359. Р. 85–90. doi: 10.1126/science.aan8630.
37. Steinhardt J.J., Guenaga J., Turner H.L., McKee K. et al. Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity // Nat. Commun. 2018. Vol. 9, No. 1. Р. 877. doi: 10.1038/s41467-018-03335-4.
38. Ko S.-Y., Pegu A., Rudicell R.S., Yang Z.-y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection // Nature. 2014. Vol. 514, No. 7524. Р. 642–645. doi: 10.1038/nature13612.
39. Gaudinski M.R., Coates E.E., Houser K.V., Chen G.L. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults // PLoS Med. 2018. Vol. 15, No. 1. Р. e1002493. doi: 10.1371/journal.pmed.1002493.
40. Gautam R., Nishimura Y., Pegu A., Nason M.C. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges // Nature. 2016. Vol. 533, No. 7601. Р. 105–109. doi: 10.1038/nature17677.
41. Simek M.D., Rida W., Priddy F.H., Pung P. et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. // J. Virol. 2009. Vol. 83, No. 14. Р. 7337–7348. doi: 10.1128/JVI.00110-09.
42. Binley J.M., Wrin T., Korber B., Zwick M.B. et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies // J. Virol. 2004. Vol. 78, No. 23. Р. 13232–13252. doi: 10.1128/JVI.78.23.13232-13252.2004.
43. Babcook J.S., Leslie K.B., Olsen O.A., Salmon R.A., Schrader J.W. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities // Proc. Natl. Acad. Sci. 1996. Vol. 93, No. 15. Р. 7843–7848. doi: 10.1073/pnas.93.15.7843.
44. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning // J. Immunol. Methods. 2008. Vol. 329, No. 1–2. Р. 112–124. doi: 10.1016/j.jim.2007.09.017.
45. West A.P., Scharf L., Scheid J.F., Klein F., Bjorkman P.J., Nussenzweig M.C. Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy // Cell. 2014. Vol. 156, No. 4. Р. 633–648. doi: 10.1016/j.cell.2014.01.052.
46. Wu X., Yang Z.Y., Li Y. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 // Science. 2010. Vol. 329, No. 5993. P. 856–861. doi: 10.1126/science.1187659.
47. Rudicell R.S., Kwon Y.D., Ko S.Y. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo // J. Virol. 2014. Vol. 88 (21). P. 12669–12682. doi: 10.1128/JVI.02213–14.
48. Huang J., Kang B.H., Ishida E. et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth // Immunity. 2016. Vol. 45, No. 5. P. 1108–1121. doi: 10.1016/j.immuni.2016.10.027.
49. Julg B., Pegu A., Abbink P. et al. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys // J. Virol. 2017. Vol. 91, No. 16. P. e00498–17. doi: 10.1128/JVI.00498-17.
50. Scheid J.F., Horwitz J.A., Bar-On Y. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption // Nature. 2016. Vol. 535, No. 7613. P. 556–560. doi: 10.1038/nature18929.
51. Shingai M., Nishimura Y., Klein F. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia // Nature. 2013. Vol. 503, No. 7475. P. 277–280. doi: 10.1038/nature12746.
52. Nishimura Y., Gautam R., Chun T.W. et al. Early antibody therapy can induce long-lasting immunity to SHIV // Nature. 2017. Vol. 543, No. 7646. P. 559–563. doi: 10.1038/nature21435.
53. Sajadi M.M., Dashti A., Rikhtegaran T.Z. et al. Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses // Cell. 2018. Vol. 173 (7). P. 1783–1795. doi: 10.1016/j.cell.2018.03.061.
54. Walker L.M., Huber M., Doores K.J. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies // Nature. 2011. Vol. 477, No. 7365. P. 466–470. doi: 10.1038/nature10373
55. Mouquet H., Scharf L., Euler Z. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109, No. 47. P. E3268-E3277. doi: 10.1073/pnas.1217207109.
56. Nishimura Y., Gautam R., Chun T.W. et al. Early antibody therapy can induce long-lasting immunity to SHIV // Nature. 2017. Vol. 543, No. 7646. P. 559–563. doi: 10.1038/nature21435.
57. Sanders R.W., Derking R., Cupo A. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies // PLoS Pathog. 2013. Vol. 9, No. 9. P. e1003618. doi: 10.1371/journal.ppat.1003618.
58. Doria-Rose N.A., Bhiman J.N., Roark R.S. et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency // J. Virol. 2015. Vol. 90, No. 1. P. 76–91. doi: 10.1128/JVI.01791-15.
59. Sok D., van Gils M.J., Pauthner M. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex // Proc. Natl. Acad. Sci. USA. 2014. Vol. 111, No. 49. P. 17624–17629. doi: 10.1073/pnas.1415789111.
60. Huang J., Ofek G., Laub L. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody // Nature. 2012. Vol. 491, No. 7424. P. 406–412. doi: 10.1038/nature11544.
61. Williams L.D., Ofek G., Schätzle S. et al. Potent and broad HIV-neutralizing antibodies in memory B cells and plasma // Sci. Immunol. 2017. Vol. 2, No. 7. P. eaal2200. doi: 10.1126/sciimmunol.aal2200.
62. Wagh K., Bhattacharya T., Williamson C. et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection // PLoS Pathog. 2016. Vol. 12, No. 3. P. e1005520. doi: 10.1371/journal.ppat.1005520.
63. Julg B., Liu P.T., Wagh K. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail // Sci. Transl. Med. 2017. Vol. 9, No. 408. P. eaao4235. doi: 10.1126/scitranslmed.aao4235.
64. Pegu A., Hessell A.J., Mascola J.R., Haigwood N.L. Use of broadly neutralizing antibodies for HIV-1 prevention // Immunol. Rev. 2017. Vol. 275, No. 1. P. 296–312. doi: 10.1111/imr.12511.
65. Cavacini L.A., Samore M.H., Gambertoglio J. et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120 // AIDS Res. Hum. Retroviruses. 1998. Vol. 14, No. 7. P. 545–550. doi: 10.1089/aid.1998.14.545.
66. Caskey M., Klein F., Lorenzi J.C. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 // Nature. 2015. Vol. 522, No. 7557. P. 487–491. doi: 10.1038/nature14411.
67. Ledgerwood J.E., Coates E.E., Yamshchikov G. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults // Clin. Exp. Immunol. 2015. Vol. 182 (3). P. 289–301. doi: 10.1111/cei.12692.
68. Caskey M., Schoofs T., Gruell H. et al. Antibody 10–1074 suppresses viremia in HIV-1-infected individuals // Nat. Med. 2017. Vol. 23, No. 2. P. 185–191. doi: 10.1038/nm.4268.
69. Lynch R.M., Boritz E., Coates E.E. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection // Sci. Transl. Med. 2015. Vol. 7, No. 319. P. 319ra206. doi: 10.1126/scitranslmed.aad5752.
70. Bar K.J., Sneller M.C., Harrison L.J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption // N. Engl. J. Med. 2016. Vol. 375, No. 21. P. 2037–2050. doi: 10.1056/NEJMoa1608243.
71. Mendoza P., Gruell H., Nogueira L. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression // Nature. 2018. Vol. 561, No. 7724. P. 479–484. doi: 10.1038/s41586-018-0531-2.
72. Niessl J., Baxter A.E., Mendoza P. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity // Nat. Med. 2020. Vol. 26, No. 2. P. 222–227. doi: 10.1038/s41591-019-0747-1.
73. Bar-On Y., Gruell H., Schoofs T. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals // Nat. Med. 2018. Vol. 24, No. 11. P. 1701–1707. doi: 10.1038/s41591-018-0186-4.
74. Mahomed S., Garrett N., Karim Q.A. et al. Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07–523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial // BMJ Open. 2020. Vol. 10, No. 11. P. e042247. doi: 10.1136/bmjopen-2020-042247.
Рецензия
Для цитирования:
Глазкова Д.В., Богословская Е.В., Шипулин Г.А., Юдин С.М. Широко нейтрализующие антитела для лечения ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии. 2021;13(3):81-95. https://doi.org/10.22328/2077-9828-2021-13-3-81-95
For citation:
Glazkova D.V., Bogoslovskaya E.V., Shipulin G.A., Yudin S.M. Broadly neutralizing antibodies for the treatment of HIV infection. HIV Infection and Immunosuppressive Disorders. 2021;13(3):81-95. (In Russ.) https://doi.org/10.22328/2077-9828-2021-13-3-81-95
Просмотров: 344
.png)
Послать статью по эл. почте 